Genentech, OSI to pay $67 million over drug claims: U.S. Justice Dept

Thomson ReutersA person holds pharmaceutical tablets and capsules in illustration picture in Ljubljana

WASHINGTON (Reuters) – Pharmaceutical companies Genentech and OSI Pharmaceuticals LLC will pay $67 million to resolve allegations they made misleading statements about the effectiveness of the drug Tarceva to treat lung cancer, the U.S. Justice Department said on Monday.

San Francisco-based Genentech and Farmingdale, New York-based OSI Pharmaceuticals co-promoted Tarceva and allegedly made misleading representations to physicians and other healthcare providers about the effectiveness of the drug to treat non-small cell lung cancer, the department said in a statement.

(Reporting by Eric Beech; Editing by Mohammad Zargham)

Read the original article on Reuters. Copyright 2016. Follow Reuters on Twitter.